Sold from Big Pharma: A New Entrant in the Pharmaceutical Contract Manufacturing Industry Seeks a Capital Fix Winding Creek Pharmaceuticals

By Grandzol, Christian; Pitingolo, Edward | Business Case Journal, Summer 2012 | Go to article overview

Sold from Big Pharma: A New Entrant in the Pharmaceutical Contract Manufacturing Industry Seeks a Capital Fix Winding Creek Pharmaceuticals


Grandzol, Christian, Pitingolo, Edward, Business Case Journal


Rex Quinn enjoyed the momentary quiet on his early-spring bicycle ride from Factory 29 to his office. As he pedaled past several of the 100-plus buildings on the 300-acre site, his thoughts were interrupted by concerns about the intended expansion of Factory 29. Months before, Winding Creek Pharmaceuticals was sold from its comfortable existence within a "Big Pharma" company, and for the first time in its 60-year history, Winding Creek was competing on its own in the cutthroat contract manufacturing industry. During the due diligence process, Winding Creek's new owner, ALPHA LLC, decided to spend $10 million to expand Factory 29 after it acquired the plant. Quinn knew, unquestionably, the plant needed extra capacity to grow and achieve profitability, but was it the right time to make a large capital investment in this factory? Would a caution from him, the plant manager, matter at this late hour anyway?

Similar to the President of the fledgling company, Brice Cooper, and the Vice President of Marketing, Doug Meyer, Quinn believed Winding Creek could sell enough product to cover the factory investment, but how quickly could it generate those sales? Low-cost foreign competitors and other structural changes had besieged contract manufacturers and Winding Creek's sales team had barely been in place for three months. In an industry with long cycle times and with foreboding evidence of an impending economic contraction, Quinn wondered what would happen if the investment failed to generate a return quickly. Arriving at the administration building, Quinn racked his Winding Creek-issued bicycle, a yellow cruiser bedecked with Quinn's prominent signature: an unusually-high seat. Eager to formulate his recommendations for the Factory 29 project, Quinn strode into his office--conflicted about expanding at this time.

Company Overview

Built during World War II along the banks of the Susquehanna River to provide chemicals for explosives, the Winding Creek site lay fallow for several years until it was leased, and ultimately purchased, by Limerick Stone Pharmaceuticals in the 1950s. Over the years, the owner spent considerable resources modernizing and expanding the facilities to provide the manufacturing capability it needed. Limerick Stone allocated work among its network of plants, selecting Winding Creek to supply various chemicals based on its processing capability and occasionally having it make products for other companies.

Because of excess worldwide capacity, Limerick Stone announced in 2004 its intention to prune its production network by closing or selling a handful of its plants, one being Winding Creek. Several years later, employees were relieved to hear there was a prospective buyer for their plant, a buyer that was interested in expanding the facilities. Quinn recalled, "We were nervous that the plant was closing, but to find out that the business was growing! Things were good."

The buyer, ALPHA LLC, had neither manufacturing nor pharmaceuticals experience. ALPHA provided government-contracted services, such as maintenance on federal buildings, making it accustomed to the structure and stability of these contracts--it did not have to worry much about fluctuating demand patterns and near-term uncertainty. Recognizing its shortcomings, ALPHA hired Brice Cooper, an executive with 30 years in the industry, to run its subsidiary contract manufacturer.

Pharmaceutical Industry Overview

Cooper navigated Winding Creek's January, 2008, launch as an independent supplier for the pharmaceutical industry, an industry that was expected to reach $735-745 billion globally in 2008 (IMS Health, 2007) with the dominant share, about 38%, belonging to the United States (Mroczkowski, 2012). The industry divided into two segments: legacy and emerging. The legacy companies, typically referred to as "Big Pharma," dominated the industry and included giants such as Johnson & Johnson, Pfizer, Wyeth, Merck & Co.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Sold from Big Pharma: A New Entrant in the Pharmaceutical Contract Manufacturing Industry Seeks a Capital Fix Winding Creek Pharmaceuticals
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.